Phase 2 RCT | Lenacapavir every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV
27 Jan, 2023 | 12:00h | UTCLenacapavir administered every 26 weeks or daily in combination with oral daily antiretroviral therapy for initial treatment of HIV: a randomised, open-label, active-controlled, phase 2 trial – The Lancet HIV (link to abstract – $ for full-text)